Cytokinetics, Inc. (CYTK) Reports In-Line Q2 Loss of 13c/Share

Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.13), in-line with the analyst estimate of ($0.13).

For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Stardust Power (SDST) Tops Q2 EPS by 1c
• Prosensa Holding N.V. (RNA) Reports Q2 Loss of $1.18